MTOR and Hypertension: In the other five studies, either the incidence of hypertension did not change after conversion from a CNI to sirolimus (both retrospective, late conversion studies) [75, 99] or there were no significant differences in hypertension or antihypertensive therapy requirements in recipients receiving an mTOR inhibitor versus those receiving CNIs [50, 78, 87] (prospective, randomized studies; two high quality everolimus and one medium quality sirolimus) (Table 5).